Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

Dopamineaddict May. 15 at 9:53 PM

$ANVS canine dementia the ultimate untapped market? One can dream….

0 · Reply

LongOrShortToMakeMoney May. 15 at 9:29 PM

$ANVS look like under 2 next week

0 · Reply

moneyonthebrain May. 15 at 3:45 PM

$ANVS has enough cash to get to NDA submission in one year - at that point, the share price will be based on the 6-month Alzheimer's phase 3 results and not whatever the market is "thinking" at the moment... https://www.annovisbio.com/press-release/annovis-closes-10-million-offering-extending-cash-runway-through-phase-3-alzheimers-disease-6-month-nda-submission

1 · Reply

junkjar291 May. 15 at 2:33 PM

$ANVS Good news on AD enrollment but this POS is still red. $$AVXL $BIVI $SAVA all proved to be a scam, $INMB failed trial, $CGTX not sure, no plan for ph3. No other tiny company has reached this stage. Why this is red every day? Funding is a biggest problem, and no guarantee of success due to post-hoc analysis of ph2 data.

4 · Reply

ppl_first May. 15 at 1:46 PM

$ANVS more financing on the way. Extreme cash burn, net loss accelerating. Buying here ensures your shares become worth less. They will announce 100% enrollment and issue new shares at the same time.

2 · Reply

vondeurvom May. 15 at 1:43 PM

$ANVS added

0 · Reply

Merlintrader May. 15 at 1:37 PM

$ANVS Alzheimer’s, RAS Oncology and iNKT Cell Therapy: $ANVS, $IMRX and $INKT Enter the May 15 Biotech Watchlist https://www.merlintrader.com/alzheimer-oncology-celltherapy-may2026-update/

0 · Reply

Marypennsylvanialand May. 15 at 1:22 PM

$ANVS what if...(based on facts, not conjecture) now that the test to determine whether a person has cognitive impairment is used to only include them in the P3 study, when readouts occur, an overwhelming majority shows marked improvement? What if those who showed a dramatic improvement is previous P3 studies, where those who would have been determined to have cognitive improvement from the test that is now used to make that determination? What's the stock worth at that time? Thinking of adding considerably to an already considerable pile of stock...

1 · Reply

RoyalPurp May. 15 at 12:42 PM

$ANVS Since no one posted it yet.. https://www.annovisbio.com/press-release/annovis-provides-corporate-updates-and-reports-first-quarter-2026-financial-results

0 · Reply

wahoowa96 May. 15 at 12:07 PM

$ANVS You can still burn entire town still 👍 as Buntanetap works!

0 · Reply

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:30 AM EDT - 8 days ago

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Apr 28, 2026, 8:00 AM EDT - 17 days ago

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Apr 10, 2026, 8:30 AM EDT - 5 weeks ago

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Apr 9, 2026, 8:30 AM EDT - 5 weeks ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

2026-04-02T11:54:03.000Z - 6 weeks ago

Annovis Bio secures U.S. patent for buntanetap

Apr 2, 2026, 7:30 AM EDT - 6 weeks ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Annovis Publishes Historical Review of Buntanetap in The Scientist

2026-03-19T11:56:46.000Z - 2 months ago

Annovis Bio enters partnership with NeuroRPM

Mar 19, 2026, 7:30 AM EDT - 2 months ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 2 months ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

2026-03-16T11:41:50.000Z - 2 months ago

Annovis Bio sees cash runway to 3Q26

2026-03-16T11:35:20.000Z - 2 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

Mar 16, 2026, 7:30 AM EDT - 2 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 3, 2026, 8:00 AM EST - 2 months ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

2026-02-12T13:21:18.000Z - 3 months ago

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

Feb 12, 2026, 8:00 AM EST - 3 months ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

2025-12-18T21:40:13.000Z - 5 months ago

Annovis Bio reports open-label extension study for Parkinson’s disease patients

Dec 18, 2025, 4:35 PM EST - 5 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 5 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 5 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 6 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

2025-11-18T14:39:45.000Z - 6 months ago

Annovis announces FDA meeting to discuss PDD program

Nov 18, 2025, 8:00 AM EST - 6 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

2025-11-17T13:10:41.000Z - 6 months ago

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Nov 17, 2025, 8:00 AM EST - 6 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

2025-11-12T13:11:18.000Z - 6 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:10:52.000Z - 6 months ago

Annovis Bio sees cash runway to 3Q26

Nov 12, 2025, 8:00 AM EST - 6 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

2025-11-06T13:32:03.000Z - 6 months ago

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

Nov 6, 2025, 8:00 AM EST - 6 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

2025-10-27T12:05:25.000Z - 7 months ago

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 7 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

2025-10-10T12:36:07.000Z - 7 months ago

Annovis Bio prices 4M shares at $1.50 in registered direct offering

Oct 10, 2025, 8:31 AM EDT - 7 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

2025-10-09T11:35:21.000Z - 7 months ago

Annovis Bio announces new results from Phase 2/3 AD study of buntanetap

Oct 9, 2025, 7:30 AM EDT - 7 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

2025-09-25T11:35:16.000Z - 8 months ago

Annovis Bio appoints Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 8 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

2025-09-16T11:40:08.000Z - 8 months ago

Annovis Bio announces publication of new article in Biomolecules on buntanetap

Sep 16, 2025, 7:30 AM EDT - 8 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 10, 2025, 12:00 PM EDT - 8 months ago

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-03T10:10:15.000Z - 9 months ago

Annovis Bio price target lowered to $10 from $12 at H.C. Wainwright

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

2025-08-07T12:26:01.000Z - 10 months ago

Annovis Bio completes full patent transfer to crystal buntanetap

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 11 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 24, 2025, 4:30 PM EDT - 11 months ago

Annovis Bio Transcript: Status Update

2025-06-24T16:06:38.000Z - 11 months ago

Annovis Bio rises 16.3%

2025-06-19T10:35:07.000Z - 11 months ago

Annovis Bio says NYSE accepted plan to regain compliance

Jun 19, 2025, 6:30 AM EDT - 11 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Nov 25, 2024, 8:00 AM EST - 1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 15, 2024, 8:00 AM EDT - 1 year ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Dopamineaddict May. 15 at 9:53 PM

$ANVS canine dementia the ultimate untapped market? One can dream….

0 · Reply

LongOrShortToMakeMoney May. 15 at 9:29 PM

$ANVS look like under 2 next week

0 · Reply

moneyonthebrain May. 15 at 3:45 PM

1 · Reply

junkjar291 May. 15 at 2:33 PM

4 · Reply

ppl_first May. 15 at 1:46 PM

$ANVS more financing on the way. Extreme cash burn, net loss accelerating. Buying here ensures your shares become worth less. They will announce 100% enrollment and issue new shares at the same time.

2 · Reply

vondeurvom May. 15 at 1:43 PM

$ANVS added

0 · Reply

Merlintrader May. 15 at 1:37 PM

$ANVS Alzheimer’s, RAS Oncology and iNKT Cell Therapy: $ANVS, $IMRX and $INKT Enter the May 15 Biotech Watchlist https://www.merlintrader.com/alzheimer-oncology-celltherapy-may2026-update/

0 · Reply

Marypennsylvanialand May. 15 at 1:22 PM

1 · Reply

RoyalPurp May. 15 at 12:42 PM

$ANVS Since no one posted it yet.. https://www.annovisbio.com/press-release/annovis-provides-corporate-updates-and-reports-first-quarter-2026-financial-results

0 · Reply

wahoowa96 May. 15 at 12:07 PM

$ANVS You can still burn entire town still 👍 as Buntanetap works!

0 · Reply

ILikeDaStocks May. 15 at 11:46 AM

$ANVS In today's announcement, "Screening: On May 15, 2026 , Annovis closed enrollment to new participants after reaching a sufficient number of patients in screening to meet the trial's enrollment goal." The patients are expected to be enrolled and dosed in summer, 2026...then the 6 month and 18 month clocks begin. 👍↗️

0 · Reply

CHItraders May. 15 at 11:39 AM

📊 Annovis Bio $ANVS Q1 Earnings ❌ Earnings Miss Adj. EPS: $(0.63) YoY: ↓ 96.88% (from $(0.32))

0 · Reply

Dopamineaddict May. 15 at 10:38 AM

$ANVS This is AI generated so forgive me if it is wrong or misleading;

1 · Reply

Rigosertib1 May. 15 at 12:35 AM

$ANVS I saw both Lilly and Novartis come up to Maria after her presentation and complimented her and seemed very interested. The room was overflowing and the largest event of the day. I think people are finally seeing what she has.

3 · Reply

wahoowa96 May. 15 at 12:27 AM

$ANVS So the BIIB080 (diranersen) is a mRNA ASO developed by Ionis. Topline tau reduction they say were fine...but I think the issue was dose-response was less than linear. I don't know how they did 😭 it but mRNA sticks around got up to three days. In my Arcturus ART-032. The multi-ascending dose focused each cohort on a single dose for a month to see its effects at that specific dose over 28 days among 6 people. It was done for three different groups of participants at three doses. Probably Tau should have been cleared more forcible way at higher dose than at a lower dose. Maybe the disease progression level was at different stage to fairly compared the response levels. If the same person took the BIIB080 at different doses over three months to then dose response is worth taking a look. Anyway Buntanetap does simiithing as BIIB080 but it doesn't require poking spinal cord...can be taken orally. Hope dose response is there for Buntanetap.

4 · Reply

dwayne09 May. 14 at 8:17 PM

$ANVS these news are relevant only because they are trying to alleviate AD, but their failures only make ANVS more valuable. IMNB news is not negative to ANVS, they are targeting "brain inflammation", not sure what they are thinking frankly, but it does demonstrate the urgent need for treatment of AD, shows how FDA desperately want someone to succeed in this area. Of course we all want a successful treatment option. I think if I M N O can get fast track designation then we are locked for approval.

0 · Reply

dwayne09 May. 14 at 8:10 PM

$ANVS

0 · Reply

junkjar291 May. 14 at 4:33 PM

$ANVS INMB received FTD from FDA for their failed drug. Designation do nothing but not sure how FDA works and why market rewards such puff news? This POS is down because of this and lately it is following another failed drug $AVXL. Back in 2021 $AVXL use to coattail ANVS and SAVA but recently it is other way around.

0 · Reply

zshortcut May. 14 at 2:48 PM

$ANVS above 2.5 by the end of month

1 · Reply

moneyonthebrain May. 14 at 1:56 PM

$ANVS May slide deck has been posted; says 85% enrolled for Alzheimer's trial (slide 11)... https://cdn.prod.website-files.com/66b473381a97d1108ee4e2aa/6a05d1a4861c7421b0f4a6de_Annovis%20Corporate%20Presentation%20-%20May%202026.pdf

3 · Reply

LongOrShortToMakeMoney May. 13 at 11:06 PM

$ANVS just terrible

0 · Reply

clearvision May. 13 at 9:50 PM

$ANVS UPDATE: I am able to intermitantly smell. Feeling has returned to the soles of my feet. Constipation has disappeared. I need less carbidopa/levadopa. Anxiety is reduced. Cognition is better. Speech seems clearer. Just drove 750 mules and was not tired. Tremors are the same. Gait problems and arm swing are the same Today is my 30th day. I also take Glyteine, a glutathion precurser. And I take a a large dose of melatonin each night ( ~80 milligrams)

3 · Reply

Market Cap	76.92M
Revenue (ttm)	0.00
Net Income (ttm)	-28.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	854,585
Avg Vol	937,952
Day's Range	N/A - N/A
Shares Out	34.65M
Stochastic %K	31%
Beta	1.26
Analysts	Strong Sell
Price Target	$11.67